[HTML][HTML] Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans
…, KJA Steel, O Hemmings, A O'Byrne, N Kouphou… - Nature …, 2020 - nature.com
Antibody responses to SARS-CoV-2 can be detected in most infected individuals 10–15 d
after the onset of COVID-19 symptoms. However, due to the recent emergence of SARS-CoV-…
after the onset of COVID-19 symptoms. However, due to the recent emergence of SARS-CoV-…
[HTML][HTML] Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern
…, D Cox, RE Dickenson, RP Galao, N Kouphou… - Nature …, 2021 - nature.com
COVID-19 vaccine design and vaccination rollout need to take into account a detailed
understanding of antibody durability and cross-neutralizing potential against SARS-CoV-2 and …
understanding of antibody durability and cross-neutralizing potential against SARS-CoV-2 and …
[HTML][HTML] Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and …
…, J Seow, C Graham, S Acors, N Kouphou… - PLoS …, 2020 - journals.plos.org
There is a clear requirement for an accurate SARS-CoV-2 antibody test, both as a complement
to existing diagnostic capabilities and for determining community seroprevalence. We …
to existing diagnostic capabilities and for determining community seroprevalence. We …
[PDF][PDF] Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B. 1.1. 7 variant
C Graham, J Seow, I Huettner, H Khan, N Kouphou… - Immunity, 2021 - cell.com
Interaction of the SARS-CoV-2 Spike receptor binding domain (RBD) with the receptor
ACE2 on host cells is essential for viral entry. RBD is the dominant target for neutralizing …
ACE2 on host cells is essential for viral entry. RBD is the dominant target for neutralizing …
Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England
Background Understanding of the true asymptomatic rate of infection of SARS-CoV-2 is
currently limited, as is understanding of the population-based seroprevalence after the first wave …
currently limited, as is understanding of the population-based seroprevalence after the first wave …
Antibody levels following vaccination against SARS-CoV-2: Associations with post-vaccination infection and risk factors in two UK longitudinal studies
…, MP Garcia, D Hart, J Seow, C Graham, N Kouphou… - Elife, 2023 - elifesciences.org
Background: SARS-CoV-2 antibody levels can be used to assess humoral immune responses
following SARS-CoV-2 infection or vaccination, and may predict risk of future infection. …
following SARS-CoV-2 infection or vaccination, and may predict risk of future infection. …
[HTML][HTML] ACE2 expression in adipose tissue is associated with cardio-metabolic risk factors and cell type composition—implications for COVID-19
…, C Graham, I Huettner, S Acors, N Kouphou… - International Journal of …, 2022 - nature.com
Background COVID-19 severity varies widely. Although some demographic and cardio-metabolic
factors, including age and obesity, are associated with increasing risk of severe illness, …
factors, including age and obesity, are associated with increasing risk of severe illness, …
[HTML][HTML] Impact of the B. 1.1. 7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike
C Graham, J Seow, I Huettner, H Khan, N Kouphou… - bioRxiv, 2021 - ncbi.nlm.nih.gov
The interaction of the SARS-CoV-2 Spike receptor binding domain (RBD) with the ACE2
receptor on host cells is essential for viral entry. RBD is the dominant target for neutralizing …
receptor on host cells is essential for viral entry. RBD is the dominant target for neutralizing …
[HTML][HTML] Antibody longevity and cross-neutralizing activity following SARS-CoV-2 wave 1 and B. 1.1. 7 infections
…, RP Galao, JM Jimenez-Guardeño, N Kouphou… - MedRxiv, 2021 - ncbi.nlm.nih.gov
As SARS-CoV-2 variants continue to emerge globally, a major challenge for COVID-19
vaccination is the generation of a durable antibody response with cross-neutralizing activity …
vaccination is the generation of a durable antibody response with cross-neutralizing activity …
[HTML][HTML] Clinical utility of targeted SARS-CoV-2 serology testing to aid the diagnosis and management of suspected missed, late or post-COVID-19 infection …
…, G Betancor, MKI Tan, J Ramble, N Kouphou… - PLoS …, 2021 - journals.plos.org
During the first wave of the global COVID-19 pandemic the clinical utility and indications for
SARS-CoV-2 serological testing were not clearly defined. The urgency to deploy serological …
SARS-CoV-2 serological testing were not clearly defined. The urgency to deploy serological …